 |
| News
| Contact | Home |
| Corporate Overview | Our Team | Pipeline | Services | Technical Platform |  |
 | ||||||||
| ||||||||
| EpiVax has developed comprehensive analytical capabilities in the field of computational immunology. We are dedicated to applying our tools to reengineering therapeutic proteins and to designing new vaccines. We leverage our tools and expertise adding value to our clients’research and development efforts while we apply them to our ownpipeline of therapeutic proteins and vaccine candidates. We have extensive immunology and microbiology laboratory capabilities including the most sophisticated MHC binding assays on the market. Because our assays utilize highly purified recombinant soluble class I and class II MHC molecules rather than whole cells or lysates, we can achieve the greatest level of specificity and sensitivity. EpiVax knows the scientific, financial, and regulatory challenges faced by today’s pharmaceutical industry and applies this know-how at every step from design to execution to IND. |
| © 2006, EpiVax, Inc. All Rights Reserved. 146 Clifford St., Providence, RI 02903 ph: 401.272.2123 • fax: 401.272.7562 • service@epivax.com |
NEWS
EpiVax Presents Tolerance-inducing "Tregitopes" at Keystone Conference - January 2008
Awarded $350K Juvenile Diabetes Research Foundation Grant for Type I Diabetes - October 2007
Awarded $600K Tuberculosis Vaccine Grant - September 2007
Awarded $350K FVIII for Hemophelia Grant - July 2007
Awarded $350K Botulinum Neurotoxin Type A for Dystonia Grant - March 2007
Awarded $990K Smallpox Vaccine Grant - June 2005
Awarded $600K H. Pylori Vaccine Grant -June 2005
Signed Joint Vaccine Development Contract with Pharmaceutical Leader - February 2005
Awarded $859K Tularemia Vaccine Grant - September 2004
Below is a sampling of some of the clients EpiVax has worked with:
